Aizon launches bioreactor application for analysis and insights
Aizon has launched its Aizon Bioreactor Application, a predictive analysis and deep knowledge management application. The technology will allow pharmaceutical and biotechnology companies to leverage rich datasets generated during upstream manufacturing to detect and accurately predict deviations and outcomes. Read More
OSE, MabSilico collaborate on AI-driven mAb development
OSE Immunotherapeutics and MabSilico have partnered to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody (mAb) drug development. Read More
AstraZeneca COVID-19 vaccine recommended for conditional use in EU
The European Medicines Agency has recommended the issuance of a conditional marketing authorization for AstraZeneca's COVID-19 vaccine in the European Union (EU) for active immunization to prevent COVID-19 in individuals 18 years of age and older. Read More
J&J single-shot COVID-19 vaccine meets end points
Johnson & Johnson released efficacy and safety data from its phase III Ensemble clinical trial, which demonstrates that the investigational single-dose COVID-19 vaccine met all primary and key secondary end points. The data is based on 43,783 participants accruing 468 symptomatic cases of COVID-19. Read More
Charles River, Cypre collaborate on in vitro services
Charles River Laboratories is joining forces with Cypre to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. Charles River clients will have access to Cypre's 3D tumor model assay, Falcon-X, a move that expands Charles River's 3D in vitro testing services. Read More
Researchers develop new gene therapy vector for blood disorders
Researchers at Children's Hospital of Philadelphia have developed a new gene therapy vector for blood disorders that is safer and more effective than those currently used in gene therapy clinical trials. Read More
Pfizer, BioNTech vaccine neutralizes SARS-CoV-2 variants in vitro
Pfizer and BioNTech has released results from in vitro neutralization studies of blood sera from individuals vaccinated with its COVID-19 vaccine, providing evidence of protection against the U.K. and South African variants of SARS-CoV-2. Read More
Novavax COVID-19 vaccine phase III trial indicates up to 89% efficacy
Novavax announced that its protein-based COVID-19 vaccine candidate, NVX-CoV2373, met the primary end point in a U.K. phase III clinical trial, achieving 89.3% efficacy. The company noted that the candidate showed strong clinical efficacy against the rapidly emerging U.K. and South African variants. Read More
Valneva begins COVID-19 vaccine production
Valneva has begun production of its inactivated COVID-19 vaccine candidate in conjunction with ongoing clinical studies from which the company expects to report results in April. Read More
Scitara raises $5M to develop its DLX platform
Scitara has raised $5 million in series A financing that it plans to use to fully develop its Digital Lab Exchange (DLX) platform. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
